The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Read full articleHealthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
Written on 02/24/2026

